A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)

Summary

A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.

Timeline

Start

2005-09

Primary completion

2007-02

Completion

2008-12

Outcome

Outcome not reported

Stopped: “The overall profile does not support development for obesity”

Publications

• Results Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond). 2010 May;34(5):919-35. doi: 10.1038/ijo.2010.21. Epub 2010 Feb 16.

Drugs

Indications